// App-Quantinova.ai

2666 : Development Of a Novel Small Molecule Inhibitor Of The Mer Tyrosine Kinase For Treatment Of Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Deborah DeRyckere

Principal Investigators

  • Xiaodong Wang

  • Amanda A. Hill

  • Weihe Zhang

  • Michael A Stashko

  • Susan Sather

  • Christopher E Cummings

  • William P Janzen

  • Stephen V. Frye

  • H. Shelton Earp III

  • Douglas K. Graham

Medical Centers

  • Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC

  • Lineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

  • Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, NC

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • Department of Pediatrics, University of Colorado/Childrens Hospital Colorado, Aurora, CO

  • Department of Pediatrics, University of Colorado/Childrens Hospital Colorado, Aurora, CO

  • Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Infertility

  • Anemia

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Mitogen-activated protein kinase

  • Mitogen-activated protein kinase 3

  • Fms related tyrosine kinase 3

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved